Covid19
Conditions
Brief summary
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insufficiency or failure.
Detailed description
200 people will take part in this LSUHSC-NO and its affiliates study. The clinical site will offer study enrollment to newly diagnosed COVID-19 patients at the time of diagnosis. Contact information will be shared with study team in a HIPAA compliant manner on the same day. Within 24 hours, our Study staff will contact patient for recruitment and enrollment. Within 48 hours of enrollment, the patient will come to a study site for randomization to treatment arms, to be provided a no-cost supply of the treatment which they are assigned, and for blood draws that help determine their risk of developing severe COVID disease. Patients will be assigned to either: Arm 1: Placebo Or Arm 2: Treatment with liquid aspirin 150 mg daily. (ASA 150). Study staff will follow-up every 2 days for a total of 30 days by text/phone/telemedicine to monitor changes in their health status, hospitalization rates, and encourage adherence to the treatment arm. Between days 7 and 10 of the study, patients will undergo repeat blood draws to help ensure their safety with regards to COVID-19. If they become hospitalized due to COVID-19, their participation will extend until they are discharged from the hospital. Medical records will be reviewed to collect data including demographics, medical comorbidities, laboratory data and hospitalization course. After 30 days of treatment, weekly follow up for another 30 days will take place ensure no late, adverse events occurred.
Interventions
DRUGASA
Liquid aspirin formulation
Sponsors
Innovate Anti-Infectives
Louisiana State University Health Sciences Center in New Orleans
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Placebo and ASA 150 will be labeled to maintain blinding. The Principal Investigator and one Biostatistician will remain blinded to prevent any bias. Study staff/healthcare providers distributing the treatments to study subjects will be blinded to treatment assignment. Subjects will also be blinded to their treatment assignment.
Intervention model description
Phase 2, proof of concept study
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients \> 40 years * Written informed consent * New (within 24 hours) COVID-19 diagnosis * Serum 25OHD levels drawn at time of COVID-19 laboratory workup
Exclusion criteria
* Asymptomatic patients * Patients already taking ASA and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban. * Pregnant patients or prisoners * History of GI bleeding or peptic ulcer disease, or spontaneous bleeding from other sites * Thrombocytopenia (platelets \<130,000/uL) at time of COVID diagnosis * Anemia at time of COVID diagnosis (defined as hemoglobin level \<12 g/dl in men or \<11 g/dl in women)22 * History of chronic kidney disease * Concurrent use of nonsteroidal anti-inflammatory drugs, or steroids * Hypervitaminosis D and associated risk factors: Renal failure, Liver failure, Hyperparathyroidism, Sarcoidosis, Histoplasmosis * Known allergy to Aspirin * Inability to tolerate oral medications * Known history of aspirin-induced asthma * History of bleeding problems * Patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of ASA treatment * Patients who cannot stop taking other nonprescription NSAIDs (ibuprofen, naproxen, or others) during the 30-day course of ASA treatment * Patients requiring hospitalization (for any reason) at time of screening * Patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of COVID
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduced COVID-19 related hospitalizations | 6 months | To obtain reliable and interpretable data to inform future trials regarding our hypothesis that a 30 day treatment course of COVID patients with a novel, liquid aspirin formulation can reduce hospitalizations driven by COVID associate coagulopathy (CAC) |
Countries
United States
Contacts
Primary ContactFrank Lau, MD
Outcome results
None listed